Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
New England Journal of Medicine · 08.10.2026 · 395 (14) · 1374-1386
DOI: 10.1056/nejmoa2505723 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.10.2026. Verfasst von Peter Sasieni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Queen Mary University of London, London. Hauptthemen laut MEDLINE: Early Detection of Cancer, Mass Screening, Neoplasms, Reagent Kits, Diagnostic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
BACKGROUND: Whether screening with blood-based early-detection tests for multiple cancers in addition to usual care has clinical utility is unknown. METHODS: In a randomized, controlled trial conducted in England, we obtained peripheral blood from persons 50 to 77 years of age at up to three annual visits. After baseline blood collection, participants were randomly assigned in a 1:1 ratio to the intervention group (participants whose blood was tested) or the control group (participants whose blood was stored). Participants and trial personnel were initially unaware of the group assignments. The primary end point was stage III or IV cancer among 12 prespecified types of cancer, and a key secondary end point was stage IV cancer among the 12 prespecified types. The differences between the groups in the incidence rate (the number of first eligible events divided by person-years at risk) were measured after three screening rounds and at least 12 months of follow-up after the last participant's third visit. RESULTS: Overall, 71,122 participants were randomly assigned to the intervention group and 71,128 to the control group. The incidence rate of stage III or IV cancer (primary end point) did not differ significantly between the groups (incidence rate ratio [intervention vs. control], 1.03; 95% confidence interval [CI], 0.92 to 1.14, P = 0.63). The incidence rate ratio for stage IV cancer (a key secondary end point) after 3 screening rounds was 0.86 (95% CI, 0.74 to 1.00). Less than 1% of participants had trial-related adverse events; none were serious. CONCLUSIONS: In this trial, we did not observe a lower incidence rate of stage III or IV cancers across 12 prespecified cancers after three screening rounds with multicancer early-detection testing plus usual care than with usual care alone. Further follow-up is warranted to assess the way in which findings for stage III or IV cancers and the between-group difference in stage IV cancers evolve over time. (Funded by Grail; NHS-Galleri ClinicalTrials.gov number, NCT05611632; ISRCTN number, ISRCTN91431511.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Queen Mary University of London, London.
- NHS England, London.
- King's College London, London.
- EMS Healthcare, Cheshire, United Kingdom.
- Guy's and St. Thomas' NHS Foundation Trust, London.
- University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Thomas Round
Förderung
- Wellcome Trust
Zitieren
APA
Sasieni, P., Johnson, P., Round, T., Warwick, J., Jones, H., Dolly, S., Lee, L., Lee, Y., Kumar, H., Liang, W., Smittenaar, R., Neal, R. D., & Swanton, C. (2026). Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. New England Journal of Medicine, 395(14), 1374-1386. https://doi.org/10.1056/nejmoa2505723
Vancouver
Sasieni P, Johnson P, Round T, Warwick J, Jones H, Dolly S, et al. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. New England Journal of Medicine. 2026;395(14):1374-1386. doi:10.1056/nejmoa2505723
BibTeX
@article{Sasieni2026,
author = {Sasieni, Peter and Johnson, Peter and Round, Thomas and Warwick, Jane and Jones, Helen and Dolly, Saoirse and Lee, Lennard and Lee, Yujin and Kumar, Harpal and Liang, Wei and Smittenaar, Rebecca and Neal, Richard D and Swanton, Charles},
title = {Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {14},
pages = {1374--1386},
doi = {10.1056/nejmoa2505723}
}
EUVIMED